Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(18):1292-1301; doi:10.1093/jnci/djj358
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Inogès, S.
Right arrow Articles by Bendandi, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Inogès, S.
Right arrow Articles by Bendandi, M.
Related Collections
Right arrowEditorial about this Article
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press.

ARTICLE

Clinical Benefit Associated With Idiotypic Vaccination in Patients With Follicular Lymphoma

Susana Inogès, Mercedes Rodrìguez-Calvillo, Natalia Zabalegui, Ascensiòn Lòpez-Dìaz de Cerio, Helena Villanueva, Elena Soria, Lilia Suárez, Arancha Rodríguez-Caballero, Fernando Pastor, Ricardo García-Muñóz, Carlos Panizo, Javier Pèrez-Calvo, Ignacio Melero, Eduardo Rocha, Alberto Orfao, Maurizio Bendandi

Affiliations of authors: Lab of Immunotherapy, Oncology Division, Center for Applied Medical Research, University of Navarra, Pamplona, Spain (SI, MRC, NZ, ALD, HV, ES, MB); General Flow Cytometry Service, Center for Cancer Investigation, University of Salamanca, Salamanca, Spain (LS, ARC, AO); Department of Immunology (FP), Department of Hematology (RGM, CP, JPC, ER), Cell Therapy Area (IM), University Clinic, University of Navarra, Pamplona, Spain

Correspondence to: Maurizio Bendandi, MD, PhD, Lab of Immunotherapy, Oncology Division, Rm. 1.06, Center for Applied Medical Research (CIMA), Avda. Pio XII, 55, 31008 Pamplona (Navarra), Spain (e-mail: mbendandi{at}unav.es).

Background: Follicular lymphoma is considered incurable, although cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy can induce sequential remissions. A patient's second complete response is typically shorter than that patient's first complete response. Idiotype vaccines can elicit specific immune responses and molecular remissions in patients with follicular lymphoma. However, a clinical benefit has never been formally proven. Methods: Thirty-three consecutive follicular lymphoma patients in first relapse received six monthly cycles of CHOP-like chemotherapy. Patients who achieved a second complete response were vaccinated periodically for more than 2 years with autologous lymphoma-derived idiotype protein vaccine. Specific humoral and cellular responses were assessed, and patients were followed for disease recurrence. Statistical tests were two-sided. Results: Idiotype vaccine could be produced for 25 patients who had a second complete response. In 20 patients (80%), a humoral (13/20) and/or a cellular (18/20) idiotype-specific response was detected. The median duration of the second complete response has not been reached, but it exceeds 33 months (range = 20+ to 51+ months). None of the 20 responders relapsed while undergoing active vaccination. All responders with enough follow-up for the comparison to be made experienced a second complete response that was statistically significantly (P<.0001) longer than both their first complete response (18 of 18 patients) and than the median duration of a CHOP-induced second complete response, i.e., 13 months (20 of 20 patients). The five nonresponders all had a second complete response that was shorter (median = 10 months; range = 8–13 months) than their first complete response (median = 17 months; range = 10–39 months). Conclusions: Idiotypic vaccination induced a specific immune response in the majority of patients with follicular lymphoma. Specific immune response was associated with a dramatic and highly statistically significant increase in disease-free survival. This is the first formal demonstration of clinical benefit associated with the use of a human cancer vaccine.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Editorial about this Article

Idiotype Vaccination in Follicular Lymphoma: Knocking on the Doorway to Cure
Dan L. Longo
J Natl Cancer Inst 2006 98: 1263-1265. [Extract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
H. Qin, S.-c. Cha, S. S. Neelapu, Y. Lou, J. Wei, Y.-J. Liu, and L. W. Kwak
Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity
Blood, November 5, 2009; 114(19): 4142 - 4149.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Corthay, K. U. Lundin, K. B. Lorvik, P. O. Hofgaard, and B. Bogen
Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells
Cancer Res., July 15, 2009; 69(14): 5901 - 5907.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Freedman, S. S. Neelapu, C. Nichols, M. J. Robertson, B. Djulbegovic, J. N. Winter, J. F. Bender, D. P. Gold, R. G. Ghalie, M. E. Stewart, et al.
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
J. Clin. Oncol., June 20, 2009; 27(18): 3036 - 3043.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Z. Ai, R. Tibshirani, B. Taidi, D. Czerwinski, and R. Levy
Anti-idiotype antibody response after vaccination correlates with better overall survival in follicular lymphoma
Blood, June 4, 2009; 113(23): 5743 - 5746.
[Abstract] [Full Text] [PDF]


Home page
Am Soc Clin Oncol Ed BookHome page
M. Foglietta, S. S. Neelapu, and L. W. Kwak
Therapeutic Vaccines for Lymphoma: From Bench to Bedside
ASCO Educational Book, January 1, 2009; 2009(1): 495 - 500.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Di Nicola, R. Zappasodi, C. Carlo-Stella, R. Mortarini, S. M. Pupa, M. Magni, L. Devizzi, P. Matteucci, P. Baldassari, F. Ravagnani, et al.
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study
Blood, January 1, 2009; 113(1): 18 - 27.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
R. Zappasodi, M. Di Nicola, C. Carlo-Stella, R. Mortarini, A. Molla, C. Vegetti, S. Albani, A. Anichini, and A. M. Gianni
The effect of artificial antigen-presenting cells with preclustered anti-CD28/-CD3/-LFA-1 monoclonal antibodies on the induction of ex vivo expansion of functional human antitumor T cells
Haematologica, October 1, 2008; 93(10): 1523 - 1534.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. J. Betting, K. Kafi, A. Abdollahi-Fard, S. A. Hurvitz, and J. M. Timmerman
Sulfhydryl-Based Tumor Antigen-Carrier Protein Conjugates Stimulate Superior Antitumor Immunity against B Cell Lymphomas
J. Immunol., September 15, 2008; 181(6): 4131 - 4140.
[Abstract] [Full Text] [PDF]


Home page
CA Cancer J ClinHome page
M. Bendandi
Aiming at a Curative Strategy for Follicular Lymphoma
CA Cancer J Clin, September 1, 2008; 58(5): 305 - 317.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. A. McCormick, S. Reddy, S. J. Reinl, T. I. Cameron, D. K. Czerwinkski, F. Vojdani, K. M. Hanley, S. J. Garger, E. L. White, J. Novak, et al.
Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: Safety and immunogenicity in a phase I clinical study
PNAS, July 22, 2008; 105(29): 10131 - 10136.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
O. J. Finn
Cancer Immunology
N. Engl. J. Med., June 19, 2008; 358(25): 2704 - 2715.
[Full Text] [PDF]


Home page
Ann OncolHome page
A. O. Abdalla, P. Kokhaei, L. Hansson, H. Mellstedt, and A. Osterborg
Idiotype vaccination in patients with myeloma reduced circulating myeloma cells (CMC)
Ann. Onc., June 1, 2008; 19(6): 1172 - 1179.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
R. Houot and R. Levy
Therapeutic Vaccine for Lymphoma: Lessons Learned and Future Directions
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 3 - 11.
[Full Text] [PDF]


Home page
ASH Education BookHome page
S. S. Neelapu and L. W. Kwak
Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies
Hematology, January 1, 2007; 2007(1): 243 - 249.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
D. L. Longo
Idiotype vaccination in follicular lymphoma: knocking on the doorway to cure.
J Natl Cancer Inst, September 20, 2006; 98(18): 1263 - 1265.
[Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.